Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Iovance Biotherapeutics Inc has 452.97M shares outstanding.

As of June 30, 2026, Iovance Biotherapeutics Inc maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc posted a negative return on equity (ROE) of -40.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.76, reflecting losses generated across the asset base. The company generates approximately 302,360.21 in revenue per employee across its workforce of 940.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.18 indicates how many times Iovance Biotherapeutics Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc recorded an income tax benefit of -3.73M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -257.14M and -253.41M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc generated 284.45M in revenue and converted that into -253.41M in net income, yielding earnings per share of -0.62. EBITDA reached -224.37M, while operating income came in at -259.23M.

As of June 30, 2026, Iovance Biotherapeutics Inc holds 96.96M in cash and equivalents against 37.93M in total debt, resulting in a net debt position of -96.96M. Total book value stands at 644.26M, with working capital of 312.84M providing operational flexibility.

Iovance Biotherapeutics Inc produced -231.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -28.20M in capital expenditures, free cash flow totaled -259.43M - equivalent to -0.63 per share.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc posted a gross margin of 48.40, reflecting its pricing power and cost economics. The operating margin of -91.14 and net profit margin of -89.09 provide insight into operational efficiency.

Iovance Biotherapeutics Inc's most recent stock split took place on September 26, 2013 with a 100:1 split ratio.